• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

    1/9/23 6:51:36 AM ET
    $AYLA
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AYLA alert in real time by email
    SC 13G/A 1 zk2328987.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934

    Ayala Pharmaceutics, Inc

    (Name of Issuer)
     
    Class A Common Stock, Par Value $0.01 per Share
    (Title of Class of Securities)
     
    05465Y108

    (CUSIP Number)

    December 31, 2022
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☐ Rule 13d-1(c)
     
    ☒ Rule 13d-1(d)
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
     


     
    CUSIP No.
      
    05465Y108
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    2,991,473
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    2,991,473
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,991,473
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    20.18%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    Page 2 of 9 Pages


    CUSIP No.
      
    05465Y108
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund G.P. Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    2,991,473
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    2,991,473
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,991,473
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    20.18%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    Page 3 of 9 Pages


    CUSIP No.
      
    05465Y108
     
    1.
    Names of Reporting Persons
     
    aMoon General Partner Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    2,991,473
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    2,991,473
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,991,473
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    20.18%
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    Page 4 of 9 Pages

     

    CUSIP No.
      
    05465Y108
     
    1.
    Names of Reporting Persons
     
    Dr. Yair C. Schindel
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    2,991,473
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    2,991,473
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,991,473
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    20.18%
    12.
    Type of Reporting Person (See Instructions)
     
    IN
     

    Page 5 of 9 Pages



    Item 1(a)
    Name of Issuer
     
    Ayala Pharmaceuticals, Inc. (the “Issuer”).
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices

    Oppenheimer 4, Rehovot 7670104 Israel
     
    Item 2(a)-(b)
    Name of Person Filing; Address of Principal Business Office or, if none, Residence


    1.
    aMoon Growth Fund Limited Partnership (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    2.
    aMoon Growth Fund G.P. Limited Partnership (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    3.
    aMoon General Partner Ltd. (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    4.
    Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     
    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. 
     
    Item 2(c)
    Citizenship
             
    aMoon is a Cayman Islands exempted limited partnership; aMoon G.P. is an Israeli limited partnership; aMoon Ltd. is an Israeli company; and Schindel is an Israeli citizen. 

    Item 2(d) 
    Title of Class of Securities

    Class A Common Stock, par value $0.01 per share
     
    Item 2(e)
    CUSIP Number

    05465Y108
     
    Item 3
    If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
    Not applicable.
     
    Item 4
    Ownership

    aMoon Growth Fund Limited Partnership


    (a)
    Amount beneficially owned:  2,991,473 shares of Common Stock.

    All share percentage calculation are based on 14,820,727 shares of Common Stock outstanding as of November 1, 2022, as reported by the Issuer to the SEC on Form 10-Q on November 3, 2022.

    Page 6 of 9 Pages



    (b)
    Percent of Class: 20.18%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 2,991,473 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 2,991,473 shares of Common Stock

    aMoon Growth Fund G.P. Limited Partnership


    (a)
    Amount beneficially owned:  2,991,473 shares of Common Stock.  aMoon G.P. is the sole general partner of aMoon.  By virtue of such relationship, aMoon G.P. may be deemed to have shared voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon.

    All share percentage calculation are based on 14,820,727 shares of Common Stock outstanding as of November 1, 2022, as reported by the Issuer to the SEC on Form 10-Q on November 3, 2022.


    (b)
    Percent of Class: 20.18%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 2,991,473 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 2,991,473 shares of Common Stock

    aMoon General Partner Ltd.


    (a)
    Amount beneficially owned:  2,991,473 shares of Common Stock.  aMoon Ltd. is the sole general partner of aMoon G.P.  By virtue of such relationships, aMoon Ltd. may be deemed to have shared voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon.

    All share percentage calculation are based on 14,820,727 shares of Common Stock outstanding as of November 1, 2022, as reported by the Issuer to the SEC on Form 10-Q on November 3, 2022.


    (b)
    Percent of Class: 20.18%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 2,991,473 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 2,991,473 shares of Common Stock

    Dr. Yair C. Schindel


    (a)
    Amount beneficially owned:  2,991,473 shares of Common Stock.  Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to have shared voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon. Schindel disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon, aMoon G.P. and aMoon Ltd., except to the extent of his pecuniary interest therein, if any.

    Page 7 of 9 Pages

    All share percentage calculation are based on 14,820,727 shares of Common Stock outstanding as of November 1, 2022, as reported by the Issuer to the SEC on Form 10-Q on November 3, 2022.


    (b)
    Percent of Class: 20.18%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 2,991,473 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 2,991,473 shares of Common Stock

    Item 5
    Ownership of Five Percent or Less of a Class

    Not applicable.
     
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     
    Not applicable.
     
    Item 8
    Identification and Classification of Members of the Group
     
    Incorporated by reference to Items 2 and 4 of this Schedule 13G.
     
    Item 9
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10
    Certification

    Not applicable.
    Page 8 of 9 Pages

     
    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: January 9, 2023

      AMOON GROWTH FUND LIMITED PARTNERSHIP
    BY: AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP, ITS GENERAL PARTNER
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GENERAL PARTNER LTD.
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    DR. YAIR C. SCHINDEL
     
           

    By:
    /s/ Dr. Yair C. Schindel  

    Page 9 of 9 Pages
    Get the next $AYLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYLA

    DatePrice TargetRatingAnalyst
    12/20/2021$22.00Buy
    Maxim Group
    12/20/2021$18.00Buy
    HC Wainwright & Co.
    11/30/2021$12.00 → $17.00Hold → Buy
    Jefferies
    8/17/2021$27.00 → $25.00Outperform
    Oppenheimer
    7/13/2021$29.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/8/23 5:16:37 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.

      SC 13G - Old Ayala, Inc (0001797336) (Subject)

      2/7/23 6:01:50 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/6/23 2:49:38 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Advaxis and Ayala Pharmaceuticals Complete Merger

      REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na

      1/19/23 9:37:49 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

      REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten

      11/17/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

      REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec

      11/16/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    SEC Filings

    See more
    • SEC Form 10-K filed by Ayala Pharmaceuticals Inc.

      10-K - Old Ayala, Inc (0001797336) (Filer)

      3/31/23 6:38:48 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.

      15-12G - Old Ayala, Inc (0001797336) (Filer)

      1/30/23 3:30:02 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Old Ayala, Inc (0001797336) (Filer)

      1/25/23 4:53:46 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Martell Bridget A

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:04:06 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Orbach Pini

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:00:56 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Golan Roy

      3 - Old Ayala, Inc (0001797336) (Issuer)

      10/31/23 5:48:50 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Financials

    Live finance-specific insights

    See more
    • Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) --  Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ayala Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/20/21 7:55:57 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Ayala Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      12/20/21 6:22:04 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals upgraded by Jefferies with a new price target

      Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously

      11/30/21 6:55:03 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary